Cedric Francois Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Cedric Francois is Chief Executive Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 331,605 shares of APLS, which is worth approximately $8.24 Million. The most recent transaction as insider was on May 16, 2023, when has been sold 30,000 shares (Common Stock) at a price of $2.67 per share, resulting in proceeds of $80,100. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 332K

20.23% 3M change

5.72% 12M change

Total Value Held $8.24 Million

Cedric Francois Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 16 2023	BUY Exercise of conversion of derivative security	$80,100 $2.67 p/Share	30,000 Added 8.96%	304,655 Common Stock
Apr 27 2023	SELL Bona fide gift	-	382,946 Reduced 58.23%	274,655 Common Stock
Apr 19 2023	BUY Exercise of conversion of derivative security	$53,400 $2.67 p/Share	20,000 Added 2.95%	657,601 Common Stock
Apr 18 2023	SELL Open market or private sale	$2,460,600 $82.02 p/Share	30,000 Reduced 4.49%	637,601 Common Stock
Apr 18 2023	BUY Exercise of conversion of derivative security	$80,100 $2.67 p/Share	30,000 Added 4.3%	667,601 Common Stock
Apr 05 2023	SELL Bona fide gift	-	26,990 Reduced 4.06%	637,601 Common Stock
Apr 04 2023	SELL Bona fide gift	-	380,000 Reduced 36.38%	664,591 Common Stock
Apr 03 2023	SELL Bona fide gift	-	227,221 Reduced 17.87%	1,044,591 Common Stock
Mar 22 2023	BUY Exercise of conversion of derivative security	$860,013 $6.76 p/Share	127,221 Added 9.09%	1,271,812 Common Stock
Mar 21 2023	SELL Open market or private sale	$1,882,200 $62.74 p/Share	30,000 Reduced 2.55%	1,144,591 Common Stock
Mar 21 2023	BUY Exercise of conversion of derivative security	$80,100 $2.67 p/Share	30,000 Added 2.49%	1,174,591 Common Stock
Feb 27 2023	BUY Exercise of conversion of derivative security	$376,000 $3.76 p/Share	100,000 Added 8.03%	1,144,591 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$93,717 $58.5 p/Share	1,602 Reduced 0.15%	1,044,591 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	13,908 Added 1.31%	1,046,193 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$202,689 $51.21 p/Share	3,958 Reduced 0.38%	1,032,285 Common Stock
Jan 27 2023	SELL Payment of exercise price or tax liability	$151,924 $52.77 p/Share	2,879 Reduced 0.28%	1,036,243 Common Stock
Jan 20 2023	SELL Payment of exercise price or tax liability	$492,028 $52.05 p/Share	9,453 Reduced 0.9%	1,039,122 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	83,447 Added 7.37%	1,048,575 Common Stock
Dec 19 2022	SELL Open market or private sale	$1,466,964 $52.02 p/Share	28,200 Reduced 2.84%	965,128 Common Stock
Dec 19 2022	BUY Exercise of conversion of derivative security	$355,701 $7.13 p/Share	49,888 Added 4.78%	993,328 Common Stock
Apr 25 2022	SELL Other acquisition or disposition	-	12,500 Reduced 1.31%	943,440 Common Stock
Feb 10 2022	SELL Payment of exercise price or tax liability	$118,884 $47.12 p/Share	2,523 Reduced 0.26%	955,940 Common Stock
Jan 28 2022	SELL Payment of exercise price or tax liability	$78,106 $38.59 p/Share	2,024 Reduced 0.15%	1,338,463 Common Stock
Jan 21 2022	BUY Grant, award, or other acquisition	-	106,244 Added 7.34%	1,340,487 Common Stock
Jul 21 2021	BUY Exercise of conversion of derivative security	$62,107 $4.31 p/Share	14,410 Added 1.15%	1,234,243 Common Stock

Cedric Francois

Chief Executive Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account